Monarch Partners Asset Management LLC Immuno Gen, Inc. Transaction History

Monarch Partners Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	BUY	$4.48 - $6.47 $3.02 Million - $4.37 Million	674,845 New	674,845 $3.23 Million
Q3 2021 Nov 04, 2021	SELL	$5.02 - $6.59 $1.15 Million - $1.5 Million	-228,125 Closed	0 $0
Q2 2021 Jul 30, 2021	BUY	$5.79 - $8.6 $783,647 - $1.16 Million	135,345 Added 145.88%	228,125 $1.5 Million
Q1 2021 May 11, 2021	SELL	$6.5 - $10.53 $87,002 - $140,944	-13,385 Reduced 12.61%	92,780 $752,000
Q4 2020 Feb 04, 2021	SELL	$3.7 - $7.66 $42,476 - $87,936	-11,480 Reduced 9.76%	106,165 $685,000
Q3 2020 Nov 05, 2020	BUY	$3.45 - $4.89 $130,824 - $185,428	37,920 Added 47.56%	117,645 $424,000
Q2 2020 Jul 31, 2020	BUY	$3.32 - $5.34 $264,687 - $425,731	79,725 New	79,725 $367,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Monarch Partners Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Monarch Partners Asset Management LLC with notifications on news.